The ability to induce immune responses at the site of infection, eliciting IgA response, represents one of the main advantages [10], while a recent comparative study between qLAIV and inactivated quadrivalent influenza vaccine standard dose (QIVsd) showed that the intranasal vaccine is much more effective in preventing influenza severe cases [11, 12]. Here, CD79A is linked to influenza.